-
Je něco špatně v tomto záznamu ?
Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study
B. Ziegler, M. Bachler, H. Haberfellner, C. Niederwanger, P. Innerhofer, T. Hell, M. Kaufmann, M. Maegele, U. Martinowitz, C. Nebl, E. Oswald, H. Schöchl, B. Schenk, M. Thaler, B. Treichl, W. Voelckel, I. Zykova, C. Wimmer, D. Fries, FIinTIC study group
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie
- MeSH
- dospělí MeSH
- fibrinogen * MeSH
- lidé MeSH
- mladiství MeSH
- pilotní projekty MeSH
- prospektivní studie MeSH
- urgentní zdravotnické služby * MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Česká republika MeSH
- Německo MeSH
- Rakousko MeSH
BACKGROUND: Trauma-induced coagulopathy (TIC) substantially contributes to mortality in bleeding trauma patients. OBJECTIVE: The aim of the study was to administer fibrinogen concentrate in the prehospital setting to improve blood clot stability in trauma patients bleeding or presumed to bleed. DESIGN: A prospective, randomised, placebo-controlled, double-blinded, international clinical trial. SETTING: This emergency care trial was conducted in 12 Helicopter Emergency Medical Services (HEMS) and Emergency Doctors' vehicles (NEF or NAW) and four trauma centres in Austria, Germany and Czech Republic between 2011 and 2015. PATIENTS: A total of 53 evaluable trauma patients aged at least 18 years with major bleeding and in need of volume therapy were included, of whom 28 received fibrinogen concentrate and 25 received placebo. INTERVENTIONS: Patients were allocated to receive either fibrinogen concentrate or placebo prehospital at the scene or during transportation to the study centre. MAIN OUTCOME MEASURES: Primary outcome was the assessment of clot stability as reflected by maximum clot firmness in the FIBTEM assay (FIBTEM MCF) before and after administration of the study drug. RESULTS: Median FIBTEM MCF decreased in the placebo group between baseline (before administration of study treatment) and admission to the Emergency Department, from a median of 12.5 [IQR 10.5 to 14] mm to 11 [9.5 to 13] mm (P = 0.0226), but increased in the FC Group from 13 [11 to 15] mm to 15 [13.5 to 17] mm (P = 0.0062). The median between-group difference in the change in FIBTEM MCF was 5 [3 to 7] mm (P < 0.0001). Median fibrinogen plasma concentrations in the fibrinogen concentrate Group were kept above the recommended critical threshold of 2.0 g l-1 throughout the observation period. CONCLUSION: Early fibrinogen concentrate administration is feasible in the complex and time-sensitive environment of prehospital trauma care. It protects against early fibrinogen depletion, and promotes rapid blood clot initiation and clot stability. TRIAL REGISTRY NUMBERS: EudraCT: 2010-022923-31 and ClinicalTrials.gov: NCT01475344.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018907
- 003
- CZ-PrNML
- 005
- 20210830100459.0
- 007
- ta
- 008
- 210728s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/EJA.0000000000001366 $2 doi
- 035 __
- $a (PubMed)33109923
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Ziegler, Bernhard $u From the Department of Anaesthesiology, Perioperative Medicine and General Intensive Care Medicine, Paracelsus Medical University, Salzburg (BZ), Department of General and Surgical Critical Care Medicine, (MB, BS, DF ), Department of Anaesthesiology and Intensive Care Medicine (HH, PI, MK, EO, MT, BT), Department of Pediatrics, Pediatrics I, Intensive Care Unit, Medical University of Innsbruck, Innsbruck (CN), Department of Mathematics, Faculty of Mathematics, Computer Science and Physics, University of Innsbruck, Technikerstrasse, Austria (TH), Department of Trauma and Orthopedic Surgery, Cologne-Merheim Medical Center (CMMC), University Witten/Herdecke (UW/H), Campus Cologne-Merheim, Cologne, Germany (MM), Institute of Thrombosis and Haemostasis and the National Haemophilia Centre, The Chaim Sheba Medical Centre, Tel Hashomer, Israel (UM), Sportclinic Zillertal GmbH, Mayrhofen, Austria (CN), Department of Anaesthesiology and Intensive Care Medicine, AUVA Trauma Centre Salzburg, Academic Teaching Hospital of the Paracelsus Medical University, Salzburg, Austria (HS, WV), Department of Anesthesiology and Intensive Care, Liberec Regional Hospital, Liberec, Czech Republic (IZ), Christophorus 14, Niederöblarn, Austria (CW)
- 245 10
- $a Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study / $c B. Ziegler, M. Bachler, H. Haberfellner, C. Niederwanger, P. Innerhofer, T. Hell, M. Kaufmann, M. Maegele, U. Martinowitz, C. Nebl, E. Oswald, H. Schöchl, B. Schenk, M. Thaler, B. Treichl, W. Voelckel, I. Zykova, C. Wimmer, D. Fries, FIinTIC study group
- 520 9_
- $a BACKGROUND: Trauma-induced coagulopathy (TIC) substantially contributes to mortality in bleeding trauma patients. OBJECTIVE: The aim of the study was to administer fibrinogen concentrate in the prehospital setting to improve blood clot stability in trauma patients bleeding or presumed to bleed. DESIGN: A prospective, randomised, placebo-controlled, double-blinded, international clinical trial. SETTING: This emergency care trial was conducted in 12 Helicopter Emergency Medical Services (HEMS) and Emergency Doctors' vehicles (NEF or NAW) and four trauma centres in Austria, Germany and Czech Republic between 2011 and 2015. PATIENTS: A total of 53 evaluable trauma patients aged at least 18 years with major bleeding and in need of volume therapy were included, of whom 28 received fibrinogen concentrate and 25 received placebo. INTERVENTIONS: Patients were allocated to receive either fibrinogen concentrate or placebo prehospital at the scene or during transportation to the study centre. MAIN OUTCOME MEASURES: Primary outcome was the assessment of clot stability as reflected by maximum clot firmness in the FIBTEM assay (FIBTEM MCF) before and after administration of the study drug. RESULTS: Median FIBTEM MCF decreased in the placebo group between baseline (before administration of study treatment) and admission to the Emergency Department, from a median of 12.5 [IQR 10.5 to 14] mm to 11 [9.5 to 13] mm (P = 0.0226), but increased in the FC Group from 13 [11 to 15] mm to 15 [13.5 to 17] mm (P = 0.0062). The median between-group difference in the change in FIBTEM MCF was 5 [3 to 7] mm (P < 0.0001). Median fibrinogen plasma concentrations in the fibrinogen concentrate Group were kept above the recommended critical threshold of 2.0 g l-1 throughout the observation period. CONCLUSION: Early fibrinogen concentrate administration is feasible in the complex and time-sensitive environment of prehospital trauma care. It protects against early fibrinogen depletion, and promotes rapid blood clot initiation and clot stability. TRIAL REGISTRY NUMBERS: EudraCT: 2010-022923-31 and ClinicalTrials.gov: NCT01475344.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a urgentní zdravotnické služby $7 D004632
- 650 12
- $a fibrinogen $7 D005340
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prospektivní studie $7 D011446
- 651 _2
- $a Rakousko $7 D001317
- 651 _2
- $a Česká republika $7 D018153
- 651 _2
- $a Německo $7 D005858
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Bachler, Mirjam
- 700 1_
- $a Haberfellner, Hubert
- 700 1_
- $a Niederwanger, Christian
- 700 1_
- $a Innerhofer, Petra
- 700 1_
- $a Hell, Tobias
- 700 1_
- $a Kaufmann, Marc
- 700 1_
- $a Maegele, Marc
- 700 1_
- $a Martinowitz, Uriel
- 700 1_
- $a Nebl, Carolin
- 700 1_
- $a Oswald, Elgar
- 700 1_
- $a Schöchl, Herbert
- 700 1_
- $a Schenk, Bettina
- 700 1_
- $a Thaler, Markus
- 700 1_
- $a Treichl, Benjamin
- 700 1_
- $a Voelckel, Wolfgang
- 700 1_
- $a Zykova, Ivana
- 700 1_
- $a Wimmer, Christine
- 700 1_
- $a Fries, Dietmar
- 710 2_
- $a FIinTIC study group
- 773 0_
- $w MED00001596 $t European journal of anaesthesiology $x 1365-2346 $g Roč. 38, č. 4 (2021), s. 348-357
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33109923 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100459 $b ABA008
- 999 __
- $a ok $b bmc $g 1689865 $s 1139353
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 38 $c 4 $d 348-357 $e 20210401 $i 1365-2346 $m European journal of anaesthesiology $n Eur J Anaesthesiol $x MED00001596
- LZP __
- $a Pubmed-20210728